Pregabalin

Excerpt

Approved by the United States Food and Drug Administration (FDA) to address neuropathic pain linked to diabetic peripheral neuropathy, spinal cord injury, and postherpetic neuralgia, as well as fibromyalgia, pregabalin stands as adjunctive therapy for partial-onset seizures in adults with epilepsy. Off-label applications include generalized anxiety disorder, social anxiety disorder, bipolar disorder, insomnia, and chronic pain conditions not sanctioned by the FDA. This activity prioritizes understanding pregabalin's mechanism of action, adverse event profile, and other pivotal factors such as off-label uses, dosing, monitoring, and pertinent interactions. The article also discusses the intricacies of administration, pharmacokinetics, and clinical toxicology, spotlighting the imperative role of the interprofessional healthcare team in overseeing pregabalin therapy.